Full-Time

Principal Transmission Strategy and Planning Expert

Energy practice

Charles River Associates (CRA)

Charles River Associates (CRA)

1,001-5,000 employees

Global consulting delivering economic, litigation analysis

Compensation Overview

$175k - $250k/yr

+ Bonus

Salt Lake City, UT, USA + 4 more

More locations: Boston, MA, USA | Washington, DC, USA | Los Angeles, CA, USA | New York, NY, USA

Hybrid

Hybrid: at least 3–4 days in the office weekly; days coordinated with your team.

Category
Consulting (2)
,
Requirements
  • Bachelor’s degree in Electrical Engineering, Power Systems Engineering, Engineering Economics, or a related field.
Responsibilities
  • Lead transmission planning and strategy engagements, including regional and local transmission planning, interconnection strategy, and evaluation of transmission expansion opportunities.
Desired Qualifications
  • Master’s degree preferred in Electrical Engineering, Power Systems Engineering, Engineering Economics, or a related field.
  • 10+ years of experience in transmission planning, power system analysis, or electricity market modeling (this item is also listed under Requirements but can be considered desirable as a nuance; however it is included in Requirements to adhere to instruction).
  • Deep familiarity with RTO/ISO transmission planning processes, interconnection procedures, and cost allocation frameworks (also in Requirements).
  • Experience with power system and market modeling tools (e.g., PSS®E, PSLF, PROMOD, Aurora, or similar) and translating results into actionable insights (also in Requirements).
  • 5+ years of leadership experience, including managing project teams and overseeing complex engagements (also in Requirements).
  • Demonstrated experience engaging with regulators, utilities, developers, or large energy users on transmission-related issues (also in Requirements).
  • Proven track record in business development and client relationship management (also in Requirements).
  • Excellent written and verbal communication skills, including the ability to present to executive audiences (also in Requirements).
  • Strong problem-solving capabilities, with the ability to structure and lead analyses on ambiguous and evolving issues (also in Requirements).
  • Commitment to mentorship, team development, and collaborative project execution (also in Requirements).
Charles River Associates (CRA)

Charles River Associates (CRA)

View

CRA is a global consulting firm that offers specialized services in litigation, regulatory, financial, and management consulting. It uses economic and financial analysis, modeling, and expert testimony to support clients in disputes, regulatory matters, and strategic decisions. The firm differentiates itself through rigorous quantitative analysis, industry expertise, and a worldwide network that delivers tailored, objective insights. Its goal is to help clients achieve favorable outcomes by providing precise analyses, clear testimony, and practical recommendations.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

City of Brussels, Belgium

Founded

1978

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hit a record $201.0 million, up 10.5%.
  • Legal & Regulatory revenue grew 11.5%, showing strong demand for dispute work.
  • EFPIA highlighted CRA's March 17, 2026 pharma report, supporting policy advisory demand.

What critics are saying

  • Q1 2026 net income fell 38.2% to $11.1 million, crushing margins.
  • Operating cash flow was negative $113.9 million, while revolver borrowings reached $192.0 million.
  • Analysts expect 2026 revenue growth to slow to 4.3%, below industry growth.

What makes Charles River Associates (CRA) unique

  • CRA specializes in litigation, regulatory, financial, and management consulting for complex disputes.
  • Its experts deliver economic analysis and testimony across antitrust, damages, and strategy matters.
  • Hitesh Makhija rejoined April 16, 2026, strengthening antitrust economics capabilities.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Charles River Associates (CRA) who can refer or advise you

Benefits

Wellness Program

Flexible Work Hours

Remote Work Options

Professional Development Budget

Company News

Business Wire
Apr 2nd, 2026
CRA appoints Christine Detrick as Lead Independent Director as William Concannon retires after 26 years

Charles River Associates has announced that Director Christine Detrick will become Lead Independent Director, effective 16th July 2026, following the planned retirement of current Lead Independent Director William Concannon. Concannon's retirement will take effect at CRA's 2026 Annual Meeting of Shareholders. Concannon has served on CRA's board since 2000 and as Lead Director since 2020. He informed the board of his decision to retire to spend more time with family. Detrick has been a board member since 2020 and currently chairs the Nominating and Corporate Governance Committee. CRA is a global consulting firm specialising in economic, financial and management consulting services, headquartered in Boston with offices worldwide.

The Pharma Letter
Mar 17th, 2026
Invest in European pharma to reap dividends, report says.

Invest in European pharma to reap dividends, report says. 17 March 2026 The European Federation of Pharmaceutical Industries and Associations (EFPIA) has highlighted the findings from a report by consultants Charles River Associates (Nasdaq: CRAI) that the trade group had commissioned. This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK 16 March 2026 9 March 2026 16 February 2026 Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news 17 March 2026 Company spotlight. A private biotechnology company developing synthetic macrocyclic peptide therapeutics designed to target historically "undruggable" proteins. Unnatural Products focuses on bridging the gap between small molecules and biologics through orally available, cell-permeable macrocycles. More features in pharmaceutical. 17 March 2026

Yahoo Finance
Mar 9th, 2026
CRA International raises 2026 revenue outlook to $805M, maintains $0.57 dividend

CRA International has raised its 2026 revenue guidance to $785 million to $805 million in constant currency, signalling expectations for higher consulting demand. The company reported fourth-quarter 2025 revenue of $196.96 million and full-year 2025 revenue of $751.58 million, with net income of $54.78 million. The firm declared a quarterly dividend of $0.57 per share, payable on 20 March 2026. This marks continued cash returns to shareholders despite net debt of approximately $100.6 million. CRA's investment narrative remains tied to consulting demand driven by global mergers and acquisitions and regulatory activity. The key risk is demand cyclicality, particularly if dealmaking or enforcement activity slows sharply. Community fair value estimates for the stock range from $252 to $333 per share.

Business Wire
Mar 4th, 2026
CRA adds renowned digital economy expert Dr Steven Tadelis to strengthen antitrust testifying capabilities

Charles River Associates has appointed Dr Steven Tadelis, a professor at UC Berkeley's Haas School of Business, as a senior consultant to its Antitrust & Competition Economics Practice. Dr Tadelis specialises in e-commerce and internet economics, with research covering digital advertising effectiveness, online marketplace reputation systems and algorithmic pricing. Dr Tadelis has provided expert economic testimony in major US and Canadian litigation cases involving digital markets and participated in Federal Trade Commission hearings. He previously held senior roles at eBay Research Labs and Amazon, serving as vice president of economics and market design. The appointment strengthens CRA's testifying capabilities in antitrust and consumer protection cases involving digital platforms and internet economics.

Yahoo Finance
Feb 27th, 2026
Charles River Associates hits record annual revenue with Q4 at $197M, beats consensus despite EPS miss

Charles River Associates reported fourth-quarter revenue of $196.96 million, beating consensus estimates of $190.54 million, though earnings per share of $2.06 fell slightly short of the $2.07 consensus. The company achieved its eighth consecutive year of record annual revenue. Revenue grew 11.6% year-over-year in the fourth quarter, driven by double-digit growth in four practices: Antitrust & Competition Economics, Energy, Forensic Services, and Labor & Employment. Life Sciences and Risk, Investigations & Analytics also expanded. Geographically, North American operations increased 9.4% whilst international operations grew 21.9%. CEO Paul Maleh said strong top-line growth drove record profitability, with net income, earnings per diluted share and EBITDA each reaching new annual highs.